Skip Navigation



Journal of the National Cancer Institute Advance Access published online on April 29, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn127
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/9/610    most recent
djn127v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayes, D. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, D. F.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?

Daniel F. Hayes, Vered Stearns, James Rae, David Flockhart
on behalf of the Consortium on Breast Cancer Pharmacogenomics

Affiliations of authors: The Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH, JR); Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (VS); Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN (DF)

Correspondence to: Daniel F. Hayes, MD, The Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI (e-mail: hayesdf@umich.edu).

The first 150 words of the full text of this article appear below.

After decades of empiricism, the treatment of cancer is widely felt to be entering the era of "targeted" therapy and leading to personalized strategies for individuals with this dreaded disease. Of course, the approach to targeted therapy in oncology is not a new one. Students of breast cancer history point to Sir George Beatson's report in 1896 of the clinical improvement he observed in three young women with locally advanced breast cancer following surgical oophorectomy (1). Subsequent landmark studies by Jensen, Lippman, and McGuire, among others, demonstrated that what Beatson had actually done was remove a specific growth factor, 17β-estradiol, from its cellular target, the estrogen receptor (ER) (2–4). Clinicians now routinely use tissue ER content to individualize antiestrogen therapy for breast cancer patients (5).

This example of personalized medicine is now joined by many others (6,7). Until . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Rinaa S. Punglia, Harold J. Burstein, Eric P. Winer, and Jane C. Weeks
J Natl Cancer Inst 2008 100: 642-648. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 603. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
N. L. Henry, V. Stearns, D. A. Flockhart, D. F. Hayes, and M. Riba
Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression
Am J Psychiatry, October 1, 2008; 165(10): 1251 - 1255.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Gurwitz and W. Newman
Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
J Natl Cancer Inst, September 17, 2008; 100(18): 1331 - 1331.
[Full Text] [PDF]